Beijing InnoCare Pharma Tech Co., which is developing treatments for cancer and autoimmune diseases, is planning a Hong Kong initial public offering, people with knowledge of the matter said.
The company has been interviewing potential advisers and aims to list as soon as this year, said the people, asking not to be identified because the information is private. InnoCare could seek around $250 million from the offering, though it hasn’t set a precise fundraising target yet, one of the people said.
